Recursion Pharmaceuticals Inc Cl A (RXRX)

$6.31 -0.18 (-2.77%)
Market Cap 2.64B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.02
Volume 24,920,299
Avg Vol 29,792,484
Day's Range N/A - N/A
Shares Out 406.50M
Stochastic %K 67%
Beta 0.91
Analysts Sell
Price Target $6.67

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
WallStreetBuyDip
WallStreetBuyDip Jul. 28 at 11:22 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
firefox2778
firefox2778 Jul. 28 at 10:37 PM
$RXRX sarepta going to the moon. This should drop tomorrow
0 · Reply
nofunanymore
nofunanymore Jul. 28 at 7:34 PM
$RXRX dogshit
0 · Reply
electribuys
electribuys Jul. 28 at 7:28 PM
$RXRX double bottom
0 · Reply
Bazzzigar
Bazzzigar Jul. 28 at 7:00 PM
$RXRX INKT
0 · Reply
yellowonder
yellowonder Jul. 28 at 6:52 PM
$RXRX almost the bottom Load up
0 · Reply
Spartangio
Spartangio Jul. 28 at 6:34 PM
$RXRX SMA200 is there Around 6,24 Let us fly over it!
0 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 28 at 4:46 PM
$RXRX it be nice if Robinhood fixed level 2 market data
0 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 28 at 4:32 PM
$RXRX OUCH
0 · Reply
Noobsados
Noobsados Jul. 28 at 3:21 PM
$RXRX why the dump?
0 · Reply
Latest News on RXRX
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 3 days ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 6 days ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

What's Happening With RXRX Stock?

Jul 8, 2025, 7:10 AM EDT - 20 days ago

What's Happening With RXRX Stock?

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 6 weeks ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 7 weeks ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion to Participate in Upcoming Investor Conferences

May 30, 2025, 8:00 AM EDT - 2 months ago

Recursion to Participate in Upcoming Investor Conferences

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 3 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 3 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 3 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 3 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 3 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 3 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 3 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 5 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 5 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 5 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 5 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 5 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 6 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 7 months ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 7 months ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 7 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 8 months ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 8 months ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 9, 2024, 3:14 PM EST - 8 months ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 20, 2024, 7:00 AM EST - 8 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 13, 2024, 9:08 AM EST - 9 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 12, 2024, 4:54 PM EST - 9 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:22 AM EDT - 9 months ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 22, 2024, 8:00 AM EDT - 9 months ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 10 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:32 AM EDT - 10 months ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Oct 2, 2024, 8:00 AM EDT - 10 months ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 4, 2024, 1:03 PM EDT - 11 months ago

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Sep 3, 2024, 8:11 AM EDT - 11 months ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Aug 9, 2024, 9:00 AM EDT - 1 year ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

EXAI

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:25 AM EDT - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Aug 8, 2024, 5:37 PM EDT - 1 year ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

EXAI

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 2:41 PM EDT - 1 year ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Aug 8, 2024, 7:39 AM EDT - 1 year ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Aug 8, 2024, 7:08 AM EDT - 1 year ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

EXAI

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Aug 8, 2024, 1:32 AM EDT - 1 year ago

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 1, 2024, 6:35 PM EDT - 1 year ago

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Jun 26, 2024, 10:07 PM EDT - 1 year ago

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Recursion Announces Proposed Offering of Class A Common Stock

Jun 26, 2024, 4:06 PM EDT - 1 year ago

Recursion Announces Proposed Offering of Class A Common Stock

WallStreetBuyDip
WallStreetBuyDip Jul. 28 at 11:22 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
firefox2778
firefox2778 Jul. 28 at 10:37 PM
$RXRX sarepta going to the moon. This should drop tomorrow
0 · Reply
nofunanymore
nofunanymore Jul. 28 at 7:34 PM
$RXRX dogshit
0 · Reply
electribuys
electribuys Jul. 28 at 7:28 PM
$RXRX double bottom
0 · Reply
Bazzzigar
Bazzzigar Jul. 28 at 7:00 PM
$RXRX INKT
0 · Reply
yellowonder
yellowonder Jul. 28 at 6:52 PM
$RXRX almost the bottom Load up
0 · Reply
Spartangio
Spartangio Jul. 28 at 6:34 PM
$RXRX SMA200 is there Around 6,24 Let us fly over it!
0 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 28 at 4:46 PM
$RXRX it be nice if Robinhood fixed level 2 market data
0 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 28 at 4:32 PM
$RXRX OUCH
0 · Reply
Noobsados
Noobsados Jul. 28 at 3:21 PM
$RXRX why the dump?
0 · Reply
electribuys
electribuys Jul. 28 at 2:34 PM
$RXRX added $7 sept calls at $6.36
1 · Reply
stock_stash
stock_stash Jul. 28 at 2:10 PM
$NBIS $RXRX
0 · Reply
firefox2778
firefox2778 Jul. 28 at 12:44 PM
$RXRX this is probably one of the few serious post i saw on this board since i'm trading the name. That said, i don't think stock will rise to $10-12 like some are saying. Actually, if ER numbers are not decent, i can see this dropping. What makes me feel comfortable? Is the chart. Everything is pointing to an up move, but, if ER is not decent, chart will mean nothing.
1 · Reply
AlNittoli
AlNittoli Jul. 28 at 11:19 AM
$RXRX SO STRONG MY GOD
1 · Reply
investORnot
investORnot Jul. 28 at 11:15 AM
$RXRX earnings in a week and a half… be prepared for an absolute rippp🚀🤫
0 · Reply
Spartangio
Spartangio Jul. 28 at 11:00 AM
$RXRX 6 has been defended well Let’s go back over 7
0 · Reply
Quanticobabe40
Quanticobabe40 Jul. 28 at 10:53 AM
$RXRX come on it's been too 12 why all is slow ass moment
1 · Reply
Tobitski
Tobitski Jul. 28 at 8:34 AM
$RXRX Will there be a 🐂 run today? 🧨🚀
1 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 28 at 6:40 AM
$RXRX overnight looking good
0 · Reply
Laryngitis31
Laryngitis31 Jul. 28 at 1:11 AM
$RXRX 6.64 in Asian markets now.
1 · Reply
WeNeedMoreGodinOurLives
WeNeedMoreGodinOurLives Jul. 27 at 8:18 PM
$RXRX $7 tomorrow
0 · Reply
BillyBarue
BillyBarue Jul. 27 at 2:50 PM
$RXRX I bought this at 6, sold the pump to 10-11, then bought back in 5’s Now waiting patiently for next pump to sell If you aren’t swinging this you need to change your approach It’s not pumping to 50 or whatever 🌕 scenario you guys are waiting for anytime soon Trade what you see on the chart 📊
0 · Reply